featured
FDA Approval for Atezolizumab Plus Cobimetinib/Vemurafenib for Advanced BRAF V600–Mutated Melanoma
Written by
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- National Comprehensive Cancer Network. Cutaneous Melanoma (Version 3.2020). Last update: May 18, 2020. Accessed on July 31, 2020.
- TECENTRIQ (Atezolizumab) Prescribing information. Genentech, Inc. South San Francisco, CA. Last update: July 2020. Accessed on July 31, 2020.
- Gutzmer R, Stroyakovskiy D, Gogas H, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;395(10240):1835-1844.
Disclosure statements are available on the authors' profiles: